Subgroup analysis from phase 3 clinical trial supports efficacy of maribavir over conventional therapies in transplant recipients with cytomegalovirus infection (refractory, with or without resistance)

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today during the presidential symposium at the 47th annual meeting of the european society for blood and marrow transplantation (ebmt) announced the results from a subgroup analysis of the phase 3 tak-620-303 (solstice) trial, for the investigational drug tak-620 (maribavir), which supported the efficacy results from the overall randomized population. more than three times as many (62.8%; 76/121)
TAK Ratings Summary
TAK Quant Ranking